Header Logo

Connection

HANA EL SAHLY to Humans

Back to Details
This is a "connection" page, showing publications HANA EL SAHLY has written about Humans.
HANA EL SAHLY
Connection Strength
0.804
Humans
  1. A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples. J Infect Dis. 2026 Mar 17; 233(3):e646-e650.
    View in: PubMed
    Score: 0.027
  2. Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network. Clin Infect Dis. 2025 Oct 10; 81(Supplement_2):S89-S102.
    View in: PubMed
    Score: 0.026
  3. Central Nervous System Histoplasmosis: A Retrospective Review of Clinical Characteristics, Treatments and Outcomes With Comparison to Disseminated Histoplasmosis Without Central Nervous System Involvement. Mycoses. 2025 May; 68(5):e70068.
    View in: PubMed
    Score: 0.025
  4. Next-Generation SARS-CoV-2 Vaccine Formulations and Alternative Routes of Administration. J Infect Dis. 2025 Feb 04; 231(1):44-48.
    View in: PubMed
    Score: 0.025
  5. The Promise of New Vaccines Against Respiratory Viruses. Pediatrics. 2024 Jun 01; 153(6).
    View in: PubMed
    Score: 0.024
  6. Cumulative Febrile, Respiratory, and Gastrointestinal Illness Among Infants in Rural Guatemala and Association With Neurodevelopmental and Growth Outcomes. Pediatr Infect Dis J. 2023 09 01; 42(9):739-744.
    View in: PubMed
    Score: 0.022
  7. Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. J Infect Dis. 2022 11 11; 226(10):1731-1742.
    View in: PubMed
    Score: 0.021
  8. Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 - a review. Transl Res. 2022 04; 242:1-19.
    View in: PubMed
    Score: 0.020
  9. Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults. J Infect Dis. 2021 11 22; 224(10):1712-1719.
    View in: PubMed
    Score: 0.020
  10. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021 Nov 04; 385(19):1774-1785.
    View in: PubMed
    Score: 0.020
  11. An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine. Hum Vaccin Immunother. 2020 12 01; 16(12):3138-3145.
    View in: PubMed
    Score: 0.018
  12. CD8 Encephalitis in a Treatment-Naive and a Virologically Suppressed Patient with HIV. Can J Neurol Sci. 2019 11; 46(6):773-775.
    View in: PubMed
    Score: 0.017
  13. Hepatic abscesses due to Clostridium septicum infection and its association with colonic adenocarcinoma: a case report and literature review. Clin J Gastroenterol. 2020 Feb; 13(1):66-72.
    View in: PubMed
    Score: 0.017
  14. The Reply. Am J Med. 2019 08; 132(8):e668.
    View in: PubMed
    Score: 0.017
  15. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
    View in: PubMed
    Score: 0.016
  16. Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity. Am J Med. 2019 04; 132(4):437-446.
    View in: PubMed
    Score: 0.016
  17. Survival of an AIDS patient after infection with Acanthamoeba sp. of the central nervous system. Infection. 2017 Oct; 45(5):715-718.
    View in: PubMed
    Score: 0.015
  18. Performance of Xpert MTB/RIF in induced sputum samples at detecting Mycobacterium tuberculosis. Clin Infect Dis. 2014 Sep 15; 59(6):911-2.
    View in: PubMed
    Score: 0.012
  19. Mycobacterium tuberculosis bacteraemia: experience from a non-endemic urban centre. Clin Microbiol Infect. 2014 Mar; 20(3):263-8.
    View in: PubMed
    Score: 0.011
  20. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis. 2012 Mar 01; 205(5):703-12.
    View in: PubMed
    Score: 0.010
  21. Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas. J Clin Microbiol. 2011 Aug; 49(8):2942-5.
    View in: PubMed
    Score: 0.010
  22. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines. 2010 Oct; 9(10):1135-41.
    View in: PubMed
    Score: 0.009
  23. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clin Vaccine Immunol. 2010 Oct; 17(10):1552-9.
    View in: PubMed
    Score: 0.009
  24. Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine. 2009 Aug 06; 27(36):4905-11.
    View in: PubMed
    Score: 0.008
  25. Clinical data on Fluarix: an inactivated split seasonal influenza vaccine. Expert Rev Vaccines. 2008 Aug; 7(6):713-9.
    View in: PubMed
    Score: 0.008
  26. Pandemic H5N1 influenza vaccine development: an update. Expert Rev Vaccines. 2008 Mar; 7(2):241-7.
    View in: PubMed
    Score: 0.008
  27. Mortality associated with central nervous system tuberculosis. J Infect. 2007 Dec; 55(6):502-9.
    View in: PubMed
    Score: 0.007
  28. Serum creatinine changes in HIV-seropositive patients receiving tenofovir. AIDS. 2006 Mar 21; 20(5):786-7.
    View in: PubMed
    Score: 0.007
  29. A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults. J Infect Dis. 2026 Mar 17; 233(3):e641-e645.
    View in: PubMed
    Score: 0.007
  30. Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials. Vaccine. 2026 Apr 02; 77:128380.
    View in: PubMed
    Score: 0.007
  31. Validating and leveraging non-SARS-CoV-2 respiratory infection as a negative control outcome in a phase 3 COVID-19 vaccine trial with extended observational follow-up. Am J Epidemiol. 2026 Jan 08; 195(1):168-177.
    View in: PubMed
    Score: 0.007
  32. Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination. Vaccine. 2026 Jan 01; 69:127959.
    View in: PubMed
    Score: 0.007
  33. Drug-resistant tuberculosis: a disease of target populations in Houston, Texas. J Infect. 2006 Jul; 53(1):5-11.
    View in: PubMed
    Score: 0.007
  34. Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine. J Infect Dis. 2025 Oct 15; 232(4):971-981.
    View in: PubMed
    Score: 0.006
  35. Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59?. Vaccine. 2025 02 15; 47:126702.
    View in: PubMed
    Score: 0.006
  36. Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials. J Infect Dis. 2024 Dec 16; 230(6):1384-1389.
    View in: PubMed
    Score: 0.006
  37. Postnatal Zika and Dengue Infection and their Effects on Neurodevelopment Among Children Living in Rural Guatemala. Pediatr Infect Dis J. 2025 Apr 01; 44(4):290-298.
    View in: PubMed
    Score: 0.006
  38. Evaluation of Vancomycin Dose Needed to Achieve 24-Hour Area Under the Concentration-Time Curve to Minimum Inhibitory Concentration Ratio Greater Than or Equal to 400 Using Pharmacometric Approaches in Pediatric Intensive Care Patients. Crit Care Explor. 2024 Oct 01; 6(10):e1159.
    View in: PubMed
    Score: 0.006
  39. SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir. J Infect Dis. 2024 Sep 23; 230(3):624-634.
    View in: PubMed
    Score: 0.006
  40. Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial. Nat Commun. 2024 09 11; 15(1):7954.
    View in: PubMed
    Score: 0.006
  41. Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases. Nat Commun. 2024 Aug 29; 15(1):7469.
    View in: PubMed
    Score: 0.006
  42. COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials. Clin Infect Dis. 2024 08 16; 79(2):364-374.
    View in: PubMed
    Score: 0.006
  43. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 06 14; 78(6):1757-1768.
    View in: PubMed
    Score: 0.006
  44. SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials. JAMA Netw Open. 2024 05 01; 7(5):e2412835.
    View in: PubMed
    Score: 0.006
  45. Recurrent tuberculosis in Houston, Texas: a population-based study. Int J Tuberc Lung Dis. 2004 Mar; 8(3):333-40.
    View in: PubMed
    Score: 0.006
  46. Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial. J Infect Dis. 2024 02 14; 229(2):327-340.
    View in: PubMed
    Score: 0.006
  47. The effect of mannose binding lectin gene polymorphisms on susceptibility to tuberculosis in different ethnic groups. Scand J Infect Dis. 2004; 36(2):106-8.
    View in: PubMed
    Score: 0.006
  48. Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial. Int J Infect Dis. 2023 Dec; 137:28-39.
    View in: PubMed
    Score: 0.006
  49. Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial. Viruses. 2023 09 29; 15(10).
    View in: PubMed
    Score: 0.006
  50. Risk of COVID-19 after natural infection or vaccination. EBioMedicine. 2023 Oct; 96:104799.
    View in: PubMed
    Score: 0.006
  51. Identification of immunodominant T cell epitopes induced by natural Zika virus infection. Front Immunol. 2023; 14:1247876.
    View in: PubMed
    Score: 0.006
  52. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat Med. 2023 09; 29(9):2334-2346.
    View in: PubMed
    Score: 0.006
  53. Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials. JAMA Netw Open. 2023 07 03; 6(7):e2323349.
    View in: PubMed
    Score: 0.006
  54. Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration. Nat Commun. 2023 06 17; 14(1):3605.
    View in: PubMed
    Score: 0.006
  55. Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection. J Infect Dis. 2023 05 29; 227(11):1303-1312.
    View in: PubMed
    Score: 0.005
  56. Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. Sci Transl Med. 2023 04 19; 15(692):eade9078.
    View in: PubMed
    Score: 0.005
  57. A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area. PLoS Negl Trop Dis. 2023 03; 17(3):e0011236.
    View in: PubMed
    Score: 0.005
  58. Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial. Vaccine. 2023 04 17; 41(16):2716-2722.
    View in: PubMed
    Score: 0.005
  59. Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials. Clin Infect Dis. 2023 01 13; 76(2):271-280.
    View in: PubMed
    Score: 0.005
  60. Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. JAMA Netw Open. 2023 01 03; 6(1):e2251974.
    View in: PubMed
    Score: 0.005
  61. Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial. Lancet Infect Dis. 2023 04; 23(4):484-495.
    View in: PubMed
    Score: 0.005
  62. Challenges and lessons learned from the rapid operationalization of a prospective cohort to study the natural history and neurodevelopmental outcomes of postnatal Zika virus infection among infants and children in rural Guatemala. PLoS Negl Trop Dis. 2022 11; 16(11):e0010480.
    View in: PubMed
    Score: 0.005
  63. Mycobacterium simiae pseudo-outbreak resulting from a contaminated hospital water supply in Houston, Texas. Clin Infect Dis. 2002 Oct 01; 35(7):802-7.
    View in: PubMed
    Score: 0.005
  64. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. Ann Intern Med. 2022 09; 175(9):1258-1265.
    View in: PubMed
    Score: 0.005
  65. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022 07 19; 3(7):100679.
    View in: PubMed
    Score: 0.005
  66. Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial. JAMA Netw Open. 2022 06 01; 5(6):e2215984.
    View in: PubMed
    Score: 0.005
  67. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022 09; 10(9):888-899.
    View in: PubMed
    Score: 0.005
  68. Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. Nat Med. 2022 04; 28(4):823-830.
    View in: PubMed
    Score: 0.005
  69. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022 03 17; 386(11):1046-1057.
    View in: PubMed
    Score: 0.005
  70. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022 Jan 07; 375(6576):43-50.
    View in: PubMed
    Score: 0.005
  71. Caregiver rating of early childhood development: Reliability and validity of the ASQ-3 in rural Guatemala. Early Hum Dev. 2021 10; 161:105453.
    View in: PubMed
    Score: 0.005
  72. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. Ann Intern Med. 2021 08; 174(8):1118-1125.
    View in: PubMed
    Score: 0.005
  73. Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease. Clin Infect Dis. 2021 04 08; 72(7):1127-1137.
    View in: PubMed
    Score: 0.005
  74. Sensitive and Prolonged Detection of Dengue Virus RNA in Whole Blood. Am J Trop Med Hyg. 2021 03 22; 104(5):1734-1736.
    View in: PubMed
    Score: 0.005
  75. Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65?years and older. Vaccine. 2021 02 22; 39(8):1339-1348.
    View in: PubMed
    Score: 0.005
  76. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 02 04; 384(5):403-416.
    View in: PubMed
    Score: 0.005
  77. Epidemiologic differences between United States- and foreign-born tuberculosis patients in Houston, Texas. J Infect Dis. 2001 Feb 01; 183(3):461-8.
    View in: PubMed
    Score: 0.005
  78. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 03 04; 384(9):795-807.
    View in: PubMed
    Score: 0.005
  79. Impact of the SARS-CoV-2 pandemic on health-care workers. Hosp Pract (1995). 2020 Oct; 48(4):161-164.
    View in: PubMed
    Score: 0.004
  80. Reliability and Validity of an Adapted and Translated Version of the Mullen Scales of Early Learning (AT-MSEL) in Rural Guatemala. Child Care Health Dev. 2020 05; 46(3):327-335.
    View in: PubMed
    Score: 0.004
  81. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
    View in: PubMed
    Score: 0.004
  82. Receptive language skills among young children in rural Guatemala: The relationship between the Test de Vocabulario en Imagenes Peabody and a translated and adapted version of the Mullen Scales of Early Learning. Child Care Health Dev. 2019 09; 45(5):702-708.
    View in: PubMed
    Score: 0.004
  83. Optimizing PCR Detection of Zika Virus from Various Body Fluids. Am J Trop Med Hyg. 2019 02; 100(2):427-433.
    View in: PubMed
    Score: 0.004
  84. Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74?years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2018 01 29; 36(5):606-614.
    View in: PubMed
    Score: 0.004
  85. Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. Vaccine. 2017 08 24; 35(36):4730-4737.
    View in: PubMed
    Score: 0.004
  86. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. 2017 03 23; 35(13):1675-1682.
    View in: PubMed
    Score: 0.004
  87. Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial. Vaccine. 2017 02 07; 35(6):923-928.
    View in: PubMed
    Score: 0.004
  88. Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans. Clin Vaccine Immunol. 2016 Apr; 23(4):326-38.
    View in: PubMed
    Score: 0.003
  89. Gastrointestinal Coccidioidomycosis. J Clin Gastroenterol. 2015 Aug; 49(7):628-9.
    View in: PubMed
    Score: 0.003
  90. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
    View in: PubMed
    Score: 0.003
  91. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na?ve subjects. Vaccine. 2015 Sep 22; 33(39):5225-34.
    View in: PubMed
    Score: 0.003
  92. Mycobacterium avium complex-associated cholecystitis in AIDS patient: a case description and review of literature. Int J STD AIDS. 2016 11; 27(13):1218-1222.
    View in: PubMed
    Score: 0.003
  93. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
    View in: PubMed
    Score: 0.003
  94. Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. Vaccine. 2014 Oct 29; 32(47):6284-93.
    View in: PubMed
    Score: 0.003
  95. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. Vaccine. 2014 Feb 12; 32(8):1019-28.
    View in: PubMed
    Score: 0.003
  96. Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised). BMC Res Notes. 2013 May 03; 6:177.
    View in: PubMed
    Score: 0.003
  97. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
    View in: PubMed
    Score: 0.003
  98. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok?) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011 Oct 13; 29(44):7733-9.
    View in: PubMed
    Score: 0.002
  99. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011 Oct 06; 29(43):7357-63.
    View in: PubMed
    Score: 0.002
  100. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine. 2010 Apr 09; 28(17):3025-9.
    View in: PubMed
    Score: 0.002
  101. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Vaccine. 2009 Dec 11; 28(2):379-85.
    View in: PubMed
    Score: 0.002
  102. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum Vaccin. 2009 Aug; 5(8):536-44.
    View in: PubMed
    Score: 0.002
  103. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA. 2008 Oct 01; 300(13):1532-43.
    View in: PubMed
    Score: 0.002
  104. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 01; 43(9):1135-42.
    View in: PubMed
    Score: 0.002
  105. 5' dinucleotide repeat polymorphism of NRAMP1 and susceptibility to tuberculosis among Caucasian patients in Houston, Texas. Int J Tuberc Lung Dis. 2002 Sep; 6(9):818-23.
    View in: PubMed
    Score: 0.001
  106. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2000 Feb; 44(2):326-36.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.